Referenser

  1. Kamper-Jørgensen M, Grønbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose--response or threshold effect? J Hepatol. 2004;41(1):25-30.

  2. Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-9.

  3. SBU. Transient elastografi vid misstänkt leverfibros och levercirros Stockholm: Statens beredning för medicinsk och social utvärdering; 2013 [Available from: https://www.sbu.se/sv/publikationer/SBU-utvarderar/transient-elastografi-vid-misstankt-leverfibros-och-levercirros/

  4. WHO. Hepatitis: World Health Organization;  [Available from: https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030#tab=tab_1

  5. Kunskapsstyrningen. Insatsområde hepatit B och C: Sveriges regioner i samverkan; 2023 [Available from: https://kunskapsstyrningvard.se/kunskapsstyrningvard/programomradenochsamverkansgrupper/nationellaprogramomraden/npoinfektionssjukdomar/hepatitbochc.56019.html

  6. Folkhälsomyndigheten. Statistik om smittsamma sjukdomar A-Ö Stockholm: Folkhälsomyndigheten;  [Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/?filter-char=H

  7. RAV. Läkemedelsbehandling av hepatit C-virusinfektion hos vuxna och barn 2023 – Behandlingsrekommendation: Referensgruppen för Antiviral Terapi; 2023 [Available from: https://www.sls.se/rav/rekommendationer/hepatit-c-virus/

  8. RAV. Behandling av kronisk hepatit B-infektion hos vuxna och barn – Rekommendation 2019: Referensgruppen för AntiViral Terapi; 2022 [Available from: https://www.sls.se/rav/rekommendationer/hepatit-b-virus/

  9. Koff RS. Hepatitis A. Lancet. 1998;351(9116):1643-9.

  10. Folkhälsomyndigheten. Hepatit A - sjukdomsstatistik Stockholm: Folkhälsomyndigheten; 2023 [Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/hepatit-a

  11. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13-21.

  12. Folkhälsomyndigheten. Hepatit B – sjukdomsstatistik Stockholm2024 [Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/hepatit-b/

  13. Duberg AS, Lybeck C, Fält A, Montgomery S, Aleman S. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. Hepatol Commun. 2022;6(9):2418-30.

  14. Folkhälsomyndigheten. Hepatit C – sjukdomsstatistik Stockholm: Folkhälsomyndigheten; 2024 [Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/hepatit-c/

  15. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385(9973):1124-35.

  16. InfCareHepatit. Kvalitetsregistret: InfCareHepatit; 2024 [Available from: https://www.infcarehepatit.se/kvalitetsregistret

  17. Asselah T, Rizzetto M. Hepatitis D Virus Infection. N Engl J Med. 2023;389(1):58-70.

  18. Folkhälsomyndigheten. Hepatit D – sjukdomsstatistik Stockholm: Folkhälsomyndigheten; 2024 [Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/hepatit-d/

  19. Folkhälsomyndigheten. Hepatit E – sjukdomsstatistik Stockholm: Folkhälsomyndigheten; 2024 [Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/hepatit-e/

  20. Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. The Lancet. 2012;379(9835):2477-88.

  21. Folkhälsomyndigheten. Sjukdomsinformation om hepatit E Stockholm: Folkhälsomyndigheten; 2017 [Available from: https://www.folkhalsomyndigheten.se/smittskydd-beredskap/smittsamma-sjukdomar/hepatit-e/

  22. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56.

  23. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516-37.

  24. EASL-EASD-EASO. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024.

  25. Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. Gastroenterology. 2020;158(1):200-14.

  26. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-12.

  27. SGF. Utredning och handläggning av MASLD (tidigare NAFLD) - Riktlinje: Svensk gastroenterologisk förening; 2023 [Available from: https://svenskgastroenterologi.se/kunskap/fettleversjukdom-2020/

  28. Villani R, Lupo P, Sangineto M, Romano AD, Serviddio G. Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary. Diagnostics (Basel). 2023;13(7).

  29. Fuster D, Samet JH. Alcohol Use in Patients with Chronic Liver Disease. N Engl J Med. 2018;379(13):1251-61.

  30. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.

  31. Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43(12):1330-9.

  32. Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47(12):1443-8.

  33. Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, et al. Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology. 2020;159(4):1276-89.e7.

  34. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845-50.

  35. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis. 2004;24(3):217-32.

  36. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-33.

  37. EASL. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81.

  38. Philips CA, Augustine P, Yerol PK, Rajesh S, Mahadevan P. Severe alcoholic hepatitis: current perspectives. Hepat Med. 2019;11:97-108.

  39. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94.

  40. EASL. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971-1004.

  41. Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol. 2020;73(6):1496-506.

  42. SGF. Autoimmun Hepatit (AIH) – Nationell riktlinje: Svensk Gastroenterologisk Förening; 2023 [Available from: https://svenskgastroenterologi.se/kunskap/autoimmun-hepatit-aih-nationell-riktlinje/

  43. EASL. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-72.

  44. Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouillères O, Poupon R, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017;65(1):152-63.

  45. Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186-94.

  46. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871-7.

  47. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419.

  48. EASL. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806.

  49. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67(6):1298-323.

  50. Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659-702.

  51. SGF. Koloskopisk övervakning av IBD, 2023 - Riktlinje: Svensk gastroenterologisk förening; 2023 [Available from: https://svenskgastroenterologi.se/kunskap/koloskopisk-overvakning-av-ibd/

  52. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E, et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2023;17(6):827-54.

  53. Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11(7):841-6.

  54. Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol. 2016;15(2):246-53.

  55. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329-34.

  56. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res. 2009;39(9):865-73.

  57. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34(8):901-10.

  58. EASL. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502.

  59. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem. 1997;272(22):14025-8.

  60. Gallego CJ, Burt A, Sundaresan AS, Ye Z, Shaw C, Crosslin DR, et al. Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network. Am J Hum Genet. 2015;97(4):512-20.

  61. Riordan SM, Williams R. Alcohol exposure and paracetamol-induced hepatotoxicity. Addict Biol. 2002;7(2):191-206.

  62. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-30.

  63. EASL. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61.

  64. Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76(1):18-31.

  65. Zimmerman HJ. The spectrum of hepatotoxicity. Perspect Biol Med. 1968;12(1):135-61.

  66. EASL. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60.

  67. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-52.

  68. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-74.

  69. EASL. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.

  70. Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180-211.

  71. Campagna F, Montagnese S, Ridola L, Senzolo M, Schiff S, De Rui M, et al. The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017;66(1):198-208.

  72. EASL. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-24.

  73. Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23.

  74. Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024;81(1):163-83.

  75. Socialstyrelsen. Levertransplantation Stockholm: Socialstyrelsen; 2024 [Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationell-hogspecialiserad-vard/arlig-uppfoljning/tillstandsomrade/levertransplantation/

Föregående sida
För vidare läsning

Nästa sida
Tillbaka till kapitlets första sida